LimmaTech Biologics
LimmaTech Biologics AG is a Swiss biotechnology company focused on developing vaccines to prevent infections caused by antimicrobial-resistant bacterial pathogens. The company applies proprietary multivalent vaccine platform approaches, enzyme-based in vivo bioconjugation, toxoid vaccine methods and engineered E. coli antigen production to advance a pipeline of clinical-stage vaccine candidates addressing pathogens such as Shigella, Klebsiella, Staphylococcus aureus and Neisseria gonorrhoeae. Headquarters and research facilities are located in Schlieren, Switzerland.
Industries
Nr. of Employees
small (1-50)
LimmaTech Biologics
Products
Shigella tetravalent glycoconjugate vaccine candidate (Shigella4V)
A tetravalent polysaccharide–protein conjugate vaccine candidate targeting the predominant Shigella serotypes by incorporating O-antigen polysaccharides from multiple strains; being evaluated in Phase I/II clinical studies.
Multivalent toxoid vaccine candidate for Staphylococcus aureus (LBT-SA7)
A rationally designed multivalent toxoid vaccine composed of multiple inactivated toxin components from Staphylococcus aureus intended to elicit protective immune responses against toxin-mediated disease processes.
Klebsiella vaccine candidate (clinical-stage program)
A glycoconjugate vaccine candidate against Klebsiella being evaluated in clinical development as part of the company's pipeline.
Shigella tetravalent glycoconjugate vaccine candidate (Shigella4V)
A tetravalent polysaccharide–protein conjugate vaccine candidate targeting the predominant Shigella serotypes by incorporating O-antigen polysaccharides from multiple strains; being evaluated in Phase I/II clinical studies.
Multivalent toxoid vaccine candidate for Staphylococcus aureus (LBT-SA7)
A rationally designed multivalent toxoid vaccine composed of multiple inactivated toxin components from Staphylococcus aureus intended to elicit protective immune responses against toxin-mediated disease processes.
Klebsiella vaccine candidate (clinical-stage program)
A glycoconjugate vaccine candidate against Klebsiella being evaluated in clinical development as part of the company's pipeline.
Expertise Areas
- Vaccine platform development
- Glycoengineering and bioconjugation
- Toxoid vaccine development
- E. coli-based antigen production
Key Technologies
- Enzyme-based in vivo bioconjugation
- Glycoconjugate (polysaccharide–protein) vaccines
- Toxoid vaccine technology
- Multivalent vaccine design